IBio Settles Investor Suit Over Ebola Drug Plans For $1.87M
By Vince Sullivan ( April 21, 2016, 3:51 PM EDT) -- Pharmaceutical company iBio Inc. settled a putative securities class action in Delaware federal court Thursday, agreeing to pay roughly $1.87 million and attorneys' fees for allegedly fabricating a joint venture to manufacture an Ebola treatment in an effort to pump up the company's value at a time when the disease was ravaging Africa....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.